-+ 0.00%
-+ 0.00%
-+ 0.00%

Rezolute to present Phase 3 sunRIZE ersodetug data in congenital hyperinsulinism at PES meeting

PUBT·04/21/2026 11:04:04
Listen to the news
Rezolute to present Phase 3 sunRIZE ersodetug data in congenital hyperinsulinism at PES meeting
  • Rezolute scheduled an oral presentation of Phase 3 sunRIZE study results for ersodetug in congenital hyperinsulinism at Pediatric Endocrine Society Annual Meeting on May 1, 2026.
  • Presentation will include previously announced topline results, indicating therapeutic benefit with evidence of target engagement.
  • Update will also cover pre-specified analyses, offering additional support for drug activity in congenital hyperinsulinism.
  • Post-hoc analyses are set to be disclosed, aimed at reinforcing overall clinical benefit narrative for ersodetug.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rezolute Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604210700PRIMZONEFULLFEED9693708) on April 21, 2026, and is solely responsible for the information contained therein.